Bio-Rad Laboratories, Inc. (NYSE:BIO) Expected to Post Q2 2025 Earnings of $2.64 Per Share

Bio-Rad Laboratories, Inc. (NYSE:BIOFree Report) – Equities research analysts at Zacks Research boosted their Q2 2025 EPS estimates for Bio-Rad Laboratories in a note issued to investors on Tuesday, May 28th. Zacks Research analyst R. Anand now expects that the medical research company will post earnings of $2.64 per share for the quarter, up from their prior estimate of $1.95. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.40 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q1 2026 earnings at $3.20 EPS.

BIO has been the subject of several other reports. UBS Group decreased their target price on shares of Bio-Rad Laboratories from $420.00 to $385.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Citigroup lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their price objective for the company from $400.00 to $365.00 in a research report on Wednesday, April 3rd. Royal Bank of Canada cut their price objective on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. Finally, StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $461.00.

Read Our Latest Analysis on Bio-Rad Laboratories

Bio-Rad Laboratories Trading Down 1.0 %

BIO stock opened at $282.01 on Friday. The firm’s 50-day simple moving average is $299.92 and its 200 day simple moving average is $313.59. The company has a quick ratio of 4.89, a current ratio of 6.57 and a debt-to-equity ratio of 0.13. Bio-Rad Laboratories has a fifty-two week low of $261.59 and a fifty-two week high of $431.79.

Bio-Rad Laboratories (NYSE:BIOGet Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The medical research company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.25. Bio-Rad Laboratories had a negative net margin of 12.37% and a positive return on equity of 3.59%. The firm had revenue of $610.82 million for the quarter, compared to analysts’ expectations of $619.09 million. During the same period in the prior year, the company posted $3.34 earnings per share. The firm’s quarterly revenue was down 9.8% on a year-over-year basis.

Hedge Funds Weigh In On Bio-Rad Laboratories

Large investors have recently bought and sold shares of the company. Sound Income Strategies LLC acquired a new stake in shares of Bio-Rad Laboratories in the 1st quarter valued at approximately $38,000. Gladius Capital Management LP increased its position in shares of Bio-Rad Laboratories by 65.8% in the fourth quarter. Gladius Capital Management LP now owns 121 shares of the medical research company’s stock worth $39,000 after purchasing an additional 48 shares during the period. Principal Securities Inc. acquired a new stake in Bio-Rad Laboratories in the fourth quarter valued at about $41,000. GAMMA Investing LLC acquired a new stake in Bio-Rad Laboratories in the fourth quarter valued at about $42,000. Finally, EntryPoint Capital LLC acquired a new stake in Bio-Rad Laboratories in the first quarter valued at about $51,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

About Bio-Rad Laboratories

(Get Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Featured Articles

Earnings History and Estimates for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.